Abstract
Background Syphilis is a sexually transmitted bacterial infection caused by Treponema pallidum subspecies pallidum, with approximately 6.3 million annual cases globally. Over the last decade, syphilis rates have risen dramatically in many high-income countries, including in England, which has seen a greater than 150% increase. Although this increase is known to be associated with high risk sexual activity in gay, bisexual and other men who have sex with men (GBMSM), cases are rising in heterosexual men and women, and congenital syphilis cases are now seen annually. The transmission dynamics within and between sexual networks of GBMSM and heterosexuals are not well understood.
Methods To determine if whole genome sequencing could be used to identify discrete patterns of transmission, we linked national patient demographic, geospatial and behavioural metadata to whole T. pallidum genome sequences previously generated from 237 patient samples collected from across England between 2012 and 2018.
Findings Phylogenomic analysis and clustering revealed two of the eight T. pallidum sublineages detected in England dominated. These dominant sublineages exhibited different spatiotemporal trends linked to demography or behaviour, suggesting they represent different sexual networks: sublineage 1 was found throughout England and across all patient groups, whereas sublineage 14 occurred predominantly in older GBMSM and was absent from samples sequenced from the North of England. By focussing on different regions of England we were able to distinguish a local heterosexual transmission cluster from a background of transmission amongst GBMSM.
Interpretation These findings demonstrate that despite extremely close genetic relationships between T. pallidum genomes globally, genomics can still be used to identify putative transmission clusters for epidemiological follow-up, and therefore has a role to play in informing public health interventions.
Funding Wellcome funding to the Sanger Institute (#206194 and 108413/A/15/D), UKRI and NIHR (COV0335; MR/V027956/1, NIHR200125), the EDCTP (RIA2018D-249), and UKHSA.
Evidence before this study Detailed phylogenomic analyses investigating the epidemiology and transmission dynamics of Treponema pallidum are challenging due to low bacterial loads in clinical specimens, and difficulty in culturing the bacteria. We searched PubMed until August 9th 2022 using the search terms “Syphilis” or “Treponema pallidum” and “genomic” or “genome(s)” or “sequencing”, finding 23 studies describing whole genome sequencing of T. pallidum subspecies pallidum, of which two used whole genome phylogenies to investigate sexual network epidemiology, with one large study of sexual networks conducted primarily in Victoria, Australia which characterised two major circulating sublineages in that setting, as well as putative sexual transmission networks with distinct sexual behavioural characteristics and potential bridging between networks.
Added value of this study In this study, we linked national surveillance data to T. pallidum genomes, and characterised the transmission dynamics of syphilis using samples from across a whole country, in a European setting (England). Integration of national-level sociodemographic, spatiotemporal and genomic data allowed the delineation of putative sexual networks at both the national and region levels, and revealed patterns not previously detected using epidemiological or genomic data alone.
Implications of all the available evidence Our findings are consistent with findings in Australia that demonstrate genomics can identify putative sociodemographic transmission clusters. However, in that study genomic clusters included samples separated by multiple single nucleotide polymorphisms, which could represent several years of evolution. Our study explored the value of linking identical genomes, and highlights that despite technical constraints, whole genome sequencing can be used to enable outbreak exclusion and identify putative local transmission clusters for epidemiological follow-up.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MAB and NRT were supported by Wellcome funding to the Sanger Institute (#206194 and 108413/A/15/D). MM was funded by the UKRI and NIHR (COV0335; MR/V027956/1, NIHR200125) and the EDCTP (RIA2018D-249). Staff time for LT, MJC, RP, HC, KS, HF, patient metadata retrieval and analyses were funded internally by UKHSA. This research was funded in whole, or in part, by the Wellcome Trust (#206194 and 108413/A/15/D). For the purpose of open access, the authors have applied a CC-BY public copyright licence to any author-accepted manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for all clinical samples was granted by the London School of Hygiene and Tropical Medicine Observational Research Ethics Committee (REF#16014) and the National Health Service (UK) Health Research Authority and Health and Care Research Wales (UK; 19/HRA/0112). UKHSA has permission to process confidential patient data under Regulation 3 (Control of Patient Information) of the Health Service Regulations 2002. Information governance advice and ethics approval for this study were granted by the PHE (now UKHSA) Research Ethics and Governance Group.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Sequencing reads for all genomes used in this study have been previously published and described, and are available at the European Nucleotide Archive (https://www.ebi.ac.uk/ena) in BioProjects PRJEB28546, PRJEB33181 and PRJNA701499. All accessions, corresponding sample identifiers and related metadata are available in Supplementary Data 1. Patient metadata for the UK genomes is available in pseudonymised form in Supplementary Data 2. UK shape files for Public Health (UKHSA) region boundaries were downloaded from the UK Office for National Statistics, available at https://geoportal.statistics.gov.uk. All sample metadata and intermediate analysis files are available at https://doi.org/10.6084/m9.figshare.21543333.v1 and https://github.com/matbeale/Syphilis_Genomic_Epi_England_2022-23.
https://doi.org/10.6084/m9.figshare.21543333.v1
https://github.com/matbeale/Syphilis_Genomic_Epi_England_2022-23
